微生物干预控制与降低澳大利亚人群血压(MICRoBIA):双盲随机交叉安慰剂对照试验的原理与设计
该试验为IIa期双盲随机交叉安慰剂对照研究,旨在验证乙酰化和丁酰化改性抗性淀粉能否通过调节肠道菌群和释放短链脂肪酸降低高血压患者血压。受试者随机接受40克/天改性抗性淀粉或安慰剂各3周,中间洗脱3周,主要终点为动态日间收缩压降低。
要点
- 改性抗性淀粉40克/天干预3周,交叉设计含3周洗脱期。
- 主要终点为动态日间收缩压较基线的降低。
- 次要终点包括循环细胞因子、免疫标志物及肠道菌群变化。
核心结论
- 该试验将首次提供合生元(益生元与后生元组合)降低人类血压的证据。
研究设计与样本
- IIa期双盲随机交叉安慰剂对照试验,受试者随机接受含40克/天改性抗性淀粉或安慰剂(玉米淀粉或普通面粉)的饮食各3周,两阶段间洗脱3周。
关键数值与推荐
- 主要终点为动态日间收缩压的降低。
- 次要终点包括循环细胞因子、免疫标志物变化及肠道菌群调节。
- 血压测量包括诊室、家庭和24小时动态设备,动脉僵硬度用颈-股脉搏波速度评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension is a prevalent chronic disease worldwide that remains poorly controlled. Recent studies support the concept that the gut microbiota is involved in the development of hypertension and that dietary fibre intake may act through the gut microbiota to lower blood pressure (BP). Resistant starch is a type of prebiotic fibre which is metabolised by commensal bacteria in the colon to produce short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate. Previous work in pre-clinical models provides strong evidence that both prebiotic fibre as well as SCFAs (i.e. postbiotics) can prevent the development of hypertension. The aim of this clinical trial is to determine if acetylated and butyrylated modified resistant starch can decrease BP of hypertensive individuals via the modulation of the gut microbiota and release of high levels of SCFAs. METHODS: This is a phase IIa double-blinded, randomised, cross-over, placebo controlled trial. Participants are randomly allocated to receive either a diet containing 40 g/day of the modified resistant starch or placebo (corn starch or regular flour) for 3 weeks on each diet, with a 3-week washout period between the two diets. BP is measured in the office, at home, and using a 24-h ambulatory device. Arterial stiffness is measured using carotid-to-femoral pulse wave velocity. Our primary endpoint is a reduction in ambulatory daytime systolic BP. Secondary endpoints include changes to circulating cytokines, immune markers, and modulation to the gut microbiome. DISCUSSION: The findings of this study will provide the first evidence for the use of a combination of pre- and postbiotics to lower BP in humans. The results are expected at the end of 2021. TRIAL REGISTRATION: Australia and New Zealand Clinical Trial Registry ACTRN12619000916145 . Registered on 1 July 2019.
引用
- Rhys-Jones D, Climie RE, Gill PA, et al. Microbial Interventions to Control and Reduce Blood Pressure in Australia (MICRoBIA): rationale and design of a double-blinded randomised cross-over placebo controlled trial. Trials. 2021. PMID: 34315522. doi:10.1186/s13063-021-05468-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。